Compound: Atomoxetine
SMILES: O(c1c(cccc1)C)[C@@H](c2ccccc2)CCNC
InChIKey: VHGCDTVCOLNTBX-QGZVFWFLSA-N
Synonyms: Atomoxetine, 83015-26-3, Tomoxetine, (-)-Tomoxetine, Tomoxetina, Tomoxetinum, Tomoxetinum [Latin], Atomoxetina, ASW034S0B8, methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine, DTXSID9044297, Benzenepropanamine, N-methyl-gamma-(2-methylphenoxy)-, (gammaR)-, CHEBI:127342, AD313 COMPONENT ATOMOXETINE, AD-313 COMPONENT ATOMOXETINE, Tomoxetinum (Latin), methyl((3R)-3-(2-methylphenoxy)-3-phenylpropyl)amine, atomoxetinum, RefChem:56721, DTXCID7024297, N06BA09, (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine, Tomoxetina [Spanish], Strattera, (R)-Tomoxetine, (R)-N-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine, A1LX4, Tomoxetine [INN], Atomoxetine [INN], CHEMBL641, Atomoxetine [INN:BAN], UNII-ASW034S0B8, HSDB 7352, MFCD06804608, Tocris-2011, Atomoxetine (USP/INN), ATOMOXETINE [MI], PST1 - Psychostimulants, ATOMOXETINE [HSDB], ATOMOXETINE [VANDF], SCHEMBL34268, ATOMOXETINE [WHO-DD], GTPL7118, orb1705357, SCHEMBL29440242, VHGCDTVCOLNTBX-QGZVFWFLSA-N, (3R)-N-methyl-3-(2-methylphenoxy)-3-phenyl-propan-1-amine, AD109 COMPONENT ATOMOXETINE, BDBM50366567, EBC-11211, PDSP1_000504, PDSP2_000502, AD-109 COMPONENT ATOMOXETINE, AKOS015961834, AC-5316, DB00289, NCGC00025345-01, AC-25548, HY-107370, NS00000414, D07473, AB00698501_08, EN300-17832026, Q417240, BRD-K20141153-001-01-6, BRD-K20141153-003-03-8, BRD-K20141153-003-12-9, BRD-K20141153-003-13-7, 1027094-45-6
Theoretical properties:
molecular_formula: C17H21NO
molecular_weight: 255.35 g/mol
exact_mass: 255.162314293 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 6
heavy_atom_count: 19
topological_polar_surface_area: 21.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
boiling_point: 64-65 ºC at 0.760 mmHg
melting_point: 161-165 ºC
Descriptions:
pubchem: Atomoxetine is a secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents. It has a role as an antidepressant, an adrenergic uptake inhibitor, a xenobiotic and an environmental contaminant. It is a member of toluenes, an aromatic ether and a secondary amino compound.
chebi: A  secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.
chembl: ATOMOXETINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Atomoxetine, sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome (CDS). It may be used alone or along with psychostimulant medication. It enhances the executive functions of self-motivation, sustained attention, inhibition, working memory, reaction time, and emotional self-regulation. Use of atomoxetine is only recommended for those who are at least six years old. It is taken orally. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate.
Common side effects of atomoxetine include abdominal pain, decreased appetite, nausea, feeling tired, and dizziness. Serious side effects may include angioedema, liver problems, stroke, psychosis, heart problems, suicide, and aggression. There is a lack of data regarding its safety during pregnancy; as of 2019, its safety during pregnancy and for use during breastfeeding is not certain.
It was approved for medical use in the United States in 2002. In 2023, it was the 161st most commonly prescribed medication in the United States, with more than 3 million prescriptions.